Tirofiban is a non-peptide selective glycoprotein (GP) IIb/IIIa receptor inhibitor that reversibly
inhibits fibrinogen-dependent platelet aggregation and subsequent formation of thrombi …

BACKGROUND: In 2003, Higashida et al proposed the Thrombolysis In Cerebral Infarction
scale to evaluate angiographic intracranial flow. Our aim is to review how subsequently …

Background and Purpose—The authors present an overview of the current evidence and
management recommendations for evaluation and treatment of adults with acute ischemic …

Despite years of research and pioneering clinical work, stroke remains a massive public
health concern. Since 1996, we have lived in the era of US Food and Drug Administration …

Background and Purpose—Strokes secondary to acute internal carotid artery (ICA)
occlusion are associated with extremely poor prognosis. The best treatment approach to …

About 15 million strokes occur each year worldwide. As the number one cause of morbidity
and acquired disability, stroke is a major drain on public health-care funding, due to long …

Background and Purpose—This is a retrospective review of patients who underwent
endovascular recanalization≥ 8 hours after acute ischemic stroke symptom onset, including …

Objective: In this study, we aimed to evaluate the safety and efficiency of low dose intra-
arterial tirofiban in mechanical thrombectomy of acute ischemic stroke patients to facilitate …

BACKGROUND AND PURPOSE: The purpose of this study was to evaluate preliminarily the
efficacy and safety of intravenous tirofiban combined with intra-arterial pharmacologic and …

Stroke is an important complication after cardiac catheterization procedures, resulting in
death and disability for thousands of patients each year. Common risk factors include …